Your browser doesn't support javascript.
loading
The impact of adjuvant EGFR-TKIs and 14-gene molecular assay on stage I non-small cell lung cancer with sensitive EGFR mutations.
Jiang, Yu; Lin, Yuechun; Fu, Wenhai; He, Qihua; Liang, Hengrui; Zhong, Ran; Cheng, Ran; Li, Bingliang; Wen, Yaokai; Wang, Huiting; Li, Jianfu; Li, Caichen; Xiong, Shan; Chen, Songan; Xiang, Jianxing; Mann, Michael J; He, Jianxing; Liang, Wenhua.
Afiliação
  • Jiang Y; National Clinical Research Center for Respiratory Disease, Guangzhou, China.
  • Lin Y; Departments of Thoracic Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
  • Fu W; National Clinical Research Center for Respiratory Disease, Guangzhou, China.
  • He Q; Departments of Thoracic Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
  • Liang H; National Clinical Research Center for Respiratory Disease, Guangzhou, China.
  • Zhong R; Departments of Thoracic Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
  • Cheng R; National Clinical Research Center for Respiratory Disease, Guangzhou, China.
  • Li B; Departments of Thoracic Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
  • Wen Y; National Clinical Research Center for Respiratory Disease, Guangzhou, China.
  • Wang H; Departments of Thoracic Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
  • Li J; National Clinical Research Center for Respiratory Disease, Guangzhou, China.
  • Li C; Departments of Thoracic Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
  • Xiong S; National Clinical Research Center for Respiratory Disease, Guangzhou, China.
  • Chen S; Departments of Thoracic Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
  • Xiang J; Department of Cardiac Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
  • Mann MJ; Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, Shanghai, China.
  • He J; National Clinical Research Center for Respiratory Disease, Guangzhou, China.
  • Liang W; Departments of Thoracic Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
EClinicalMedicine ; 64: 102205, 2023 Oct.
Article em En | MEDLINE | ID: mdl-37745018
ABSTRACT

Background:

Currently, the role of EGFR-TKIs as adjuvant therapy for stage I, especially IA NSCLC, after surgical resection remains unclear. We aimed to compare the effect of adjuvant EGFR-TKIs with observation in such patients by incorporating an established 14-gene molecular assay for risk stratification.

Methods:

This retrospective cohort study was conducted at the First Affiliated Hospital of Guangzhou Medical University (Study ID ChNCRCRD-2022-GZ01). From March 2013 to February 2019, completely resected stage I NSCLC (8th TNM staging) patients with sensitive EGFR mutation were included. Patients with eligible samples for molecular risk stratification were subjected to the 14-gene prognostic assay. Inverse probability of treatment weighting (IPTW) was employed to minimize imbalances in baseline characteristics.

Findings:

A total of 227 stage I NSCLC patients were enrolled, with 55 in EGFR-TKI group and 172 in the observation group. The median duration of follow-up was 78.4 months. After IPTW, the 5-year DFS (HR = 0.30, 95% CI, 0.14-0.67; P = 0.003) and OS (HR = 0.26, 95% CI, 0.07-0.96; P = 0.044) of the EGFR-TKI group were significantly better than the observation group. For subgroup analyses, adjuvant EGFR-TKIs were associated with favorable 5-year DFS rates in both IA (100.0% vs. 84.5%; P = 0.007), and IB group (98.8% vs. 75.3%; P = 0.008). The 14-gene assay was performed in 180 patients. Among intermediate-high-risk patients, EGFR-TKIs were associated with a significant improvement in 5-year DFS rates compared to observation (96.0% vs. 70.5%; P = 0.012), while no difference was found in low-risk patients (100.0% vs. 94.9%; P = 0.360).

Interpretation:

Our study suggested that adjuvant EGFR-TKI might improve DFS and OS of stage IA and IB EGFR-mutated NSCLC, and the 14-gene molecular assay could help patients that would benefit the most from treatment.

Funding:

This work was supported by China National Science Foundation (82022048, 82373121).
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: EClinicalMedicine Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: EClinicalMedicine Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China
...